1st Trop-2 ADC Trodelvy expands indication to metastatic HR+/HER2- breast cancer

CAR-T Digest - August 2020

14 Feb 2025: 1st Trop-2 ADC Trodelvy expands indication to metastatic HR+/HER2- breast cancer

Trodelvy (Sacituzumab govitecan) received expanded approval in Korea to treat metastatic HR+/HER2- breast cancer resistant to endocrine therapy
The approval is based on the Phase 3 TROPiCS-02 study, showing significant improvement in progression-free and overall survival
Trodelvy reduced disease progression and death risk by 34% compared to standard chemotherapy, with a median overall survival of 14.4 months
It became the first ADC to show a survival benefit in both metastatic triple-negative and HR+/HER2- breast cancer
Gilead Sciences Korea aims to expand treatment access and improve quality of life for patients with limited options